Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — ...

On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...